Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management.
biomarkers
bleomycin
chemotherapy
germ cell tumors
high-dose
human chorionic gonadotropin
metastases
platinum
prognosis
seminoma
α-fetoprotein
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
19
3
2019
medline:
20
8
2019
entrez:
19
3
2019
Statut:
ppublish
Résumé
Germ cell tumors represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 and 35. Pure seminoma accounts for around 50% of all testicular germ cell tumors. The prognostic classification of the International Germ Cell Cancer Collaborative Group for good-prognosis seminoma includes both nodal disease and pulmonary visceral metastases. In this article, we analyzed recent data on prognosis and outcome of good-prognosis seminoma to revise the traditional classification of the disease and improve tailored treatment.
Identifiants
pubmed: 30880465
doi: 10.2217/fon-2018-0850
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng